Get out of cash NOW
Millionaire Wall Street Legend Urges Americans To Get Out Of CASH before April 27th.
Details here.
pixel

CRSP Insider Trading (CRISPR Therapeutics)

Insider Ownership Percentage: 17.10%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $103,710,937.33

CRISPR Therapeutics Insider Trading History Chart

CRISPR Therapeutics Share Price & Price History

$115.74
▼ -4.64 (-3.85%)
As of 04/9/2021 01:00 AM ET
Days: 30 | 90 | 365
Learn How to Analyze Your Market and Trading Plan
Custom-design an options strategy to fit your market outlook. This guide goes beyond the basics to help you understand how to evaluate a strategy’s risk and reward. Start with your market outlook, then hone in on your strategy based on the risk you’re willing to take.
Download Your FREE Options Trading Strategy Guide today!
pixel

CRISPR Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/22/2021Bradley J Phd BolzonDirectorSell30,374$132.37$4,020,606.3857,149  
1/19/2021James R. KasingerGeneral CounselSell27,500$204.94$5,635,850.00  
1/15/2021Lawrence Otto KleinCOOSell25,000$215.20$5,380,000.0028,666  
1/15/2021Samarth KulkarniCEOSell20,000$213.67$4,273,400.00202,989  
12/21/2020Tony W. HoVPSell23,551$149.23$3,514,515.73  
12/16/2020Bradley J Phd BolzonDirectorSell7,648$148.95$1,139,169.606,734  
12/10/2020Bradley J Phd BolzonDirectorSell33,000$143.35$4,730,550.0040,648  
12/10/2020Samarth KulkarniCEOSell20,000$142.29$2,845,800.00189,189  
12/7/2020Bradley J Phd BolzonDirectorSell171,004$154.53$26,425,248.1240,648  
11/30/2020Rodger NovakPresidentSell100,000$125.00$12,500,000.00698,007  
9/18/2020Bradley J Phd BolzonDirectorSell3,035$86.87$263,650.457,391  
9/16/2020Bradley J Phd BolzonDirectorSell8,965$86.98$779,775.707,391  
9/14/2020Bradley J Phd BolzonDirectorSell1,155$84.89$98,047.957,391  
9/10/2020Bradley J Phd BolzonDirectorSell22,845$85.36$1,950,049.207,391  
9/1/2020Bradley J Phd BolzonDirectorSell60,000$92.51$5,550,600.00  
9/1/2020Michael John TomsicekCFOSell12,000$92.26$1,107,120.0012,410  
9/1/2020Rodger NovakPresidentSell25,000$92.62$2,315,500.00651,940  
7/7/2020Rodger NovakPresidentSell25,000$90.00$2,250,000.00653,593  
7/6/2020Bradley J Phd BolzonDirectorSell20,000$82.39$1,647,800.00  
6/24/2020Lawrence Otto KleinCOOSell65,088$75.93$4,942,131.8458,666  
6/23/2020Bradley J Phd BolzonDirectorSell20,000$73.93$1,478,600.00  
6/23/2020Rodger NovakPresidentSell50,000$75.00$3,750,000.00698,007  
6/23/2020Tony W HoVPSell7,158$75.04$537,136.3240,676  
6/1/2020Samarth KulkarniCEOSell17,275$64.68$1,117,347.00188,801  
5/20/2020Samarth KulkarniCEOSell10,693$65.28$698,039.04175,833  
5/19/2020Rodger NovakPresidentSell50,000$65.00$3,250,000.00798,007  
5/11/2020Lawrence Otto KleinCOOSell25,000$60.40$1,510,000.0045,000  
11/19/2019Pablo J CagnoniDirectorSell7,500$62.00$465,000.007,500  
11/19/2019Rodger NovakPresidentSell33,618$70.00$2,353,260.0033,618  
11/12/2019Pablo J CagnoniDirectorSell7,500$55.00$412,500.007,500  
10/30/2019Pablo J CagnoniDirectorSell7,500$52.00$390,000.007,500  
7/11/2019Lawrence Otto KleinInsiderSell20,000$50.02$1,000,400.0031,579  
7/10/2019Rodger NovakPresidentSell50,000$50.00$2,500,000.00848,007  
6/17/2019Samarth KulkarniCEOSell20,000$46.00$920,000.00185,801  
6/10/2019Rodger NovakPresidentSell50,000$45.00$2,250,000.00898,007  
4/29/2019Samarth KulkarniCEOSell20,000$42.03$840,600.00186,542  
3/4/2019Rodger NovakPresidentSell85,220$40.40$3,442,888.001,024,534  
3/1/2019Rodger NovakPresidentSell8,693$40.01$347,806.931,024,534  
2/25/2019Rodger NovakPresidentSell14,780$40.00$591,200.001,033,227  
1/8/2019Rodger NovakPresidentSell17,310$35.09$607,407.901,130,697  
12/27/2018Vertex Pharmaceuticals (EuropeMajor ShareholderBuy40,198$24.93$1,002,136.14  
12/24/2018Vertex Pharmaceuticals (EuropeMajor ShareholderBuy90,742$24.08$2,185,067.36  
12/21/2018Vertex Pharmaceuticals (EuropeMajor ShareholderBuy22,742$22.58$513,514.36  
12/18/2018Kurt Von EmsterDirectorSell72,934$29.85$2,177,079.90  
7/5/2018Pablo J CagnoniDirectorSell7,500$62.00$465,000.005,816  
7/3/2018Pablo J CagnoniDirectorSell5,816$62.00$360,592.005,816  
6/5/2018Kurt Von EmsterDirectorSell920$12.51$11,509.2090,000  
6/1/2018Samarth KulkarniCEOSell15,000$69.36$1,040,400.00163,560  
5/17/2018Rodger NovakPresidentSell75,000$60.00$4,500,000.001,183,247  
5/14/2018Kurt Von EmsterDirectorSell650,000$54.39$35,353,500.005,629  
5/11/2018Kurt Von EmsterDirectorSell250,000$52.84$13,210,000.00  
5/8/2018Bradley J Phd BolzonDirectorSell128,950$50.39$6,497,790.5037,645  
4/30/2018Bradley J Phd BolzonDirectorSell30,566$50.29$1,537,164.1443,986  
4/27/2018Thomas WoiwodeDirectorSell222,258$50.11$11,137,348.38  
4/24/2018Versant Venture Capital V, L.PMajor ShareholderSell22,841$50.99$1,164,662.59  
4/23/2018Bradley J Phd BolzonDirectorSell101,994$50.68$5,169,055.9243,986  
See Full Table

SEC Filings (Institutional Ownership Changes) for CRISPR Therapeutics (NASDAQ:CRSP)

66.43% of CRISPR Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

CRISPR Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in Company
4/9/2021Ipswich Investment Management Co. Inc.27,080$3.30M0.9%-5.8%0.036%
4/8/2021Baldwin Brothers Inc. MA318$38K0.0%+367.6%0.000%
4/6/2021Liberty One Investment Management LLC1,297$0.16M0.0%+35.4%0.002%
3/12/2021DekaBank Deutsche Girozentrale16,310$2.57M0.0%+21.3%0.022%
3/8/2021Dimensional Fund Advisors LP107,647$16.50M0.0%+5.9%0.143%
3/5/2021BNC Wealth Management LLC8,964$1.37M0.9%+9.5%0.012%
3/3/2021Draper Asset Management LLC1,760$0.27M0.3%N/A0.002%
3/2/2021RBF Capital LLC4,000$0.61M0.0%N/A0.005%
3/2/2021Norges Bank563,091$86.22M0.0%N/A0.747%
3/1/2021UBS Asset Management Americas Inc.106,746$16.34M0.0%-11.5%0.142%
2/26/2021Avitas Wealth Management LLC20,894$3.20M0.6%N/A0.028%
2/25/2021Dimensional Fund Advisors LP107,647$16.50M0.0%+5.9%0.143%
2/25/2021Front Row Advisors LLC15,962$2.44M1.3%-1.2%0.021%
2/25/2021Hsbc Holdings PLC11,174$1.73M0.0%+144.4%0.015%
2/24/2021Bank Julius Baer & Co. Ltd Zurich10,084$1.54M0.0%N/A0.013%
2/23/2021Pier 88 Investment Partners LLC2,795$0.43M0.1%-66.3%0.004%
2/22/2021Retirement Group LLC323$49K0.0%N/A0.000%
2/19/2021JPMorgan Chase & Co.451,660$69.15M0.0%+11.0%0.634%
2/18/2021Capital Advisory Group Advisory Services LLC248$38K0.0%+300.0%0.000%
2/18/2021Intellectus Partners LLC8,970$1.37M0.4%-5.0%0.013%
2/18/2021Professional Planning3,708$0.57M0.2%N/A0.005%
2/18/2021Circle Wealth Management LLC1,359$0.21M0.0%N/A0.002%
2/18/2021Truist Financial Corp6,811$1.04M0.0%+77.4%0.010%
2/17/2021Financial Architects Inc2,005$0.31M0.1%N/A0.003%
2/17/2021Voloridge Investment Management LLC29,191$4.47M0.0%N/A0.041%
2/17/2021IHT Wealth Management LLC9,416$1.44M0.1%+20.6%0.013%
2/17/2021Ambassador Advisors LLC2,228$0.34M0.1%N/A0.003%
2/17/2021Mitsubishi UFJ Morgan Stanley Securities Co. Ltd.610$93K0.1%N/A0.001%
2/17/2021Cetera Investment Advisers5,111$0.78M0.0%N/A0.007%
2/17/2021Cetera Advisor Networks LLC5,317$0.81M0.0%-18.0%0.007%
2/16/2021Orbimed Advisors LLC451,800$69.18M0.6%-28.3%0.634%
2/16/2021Squarepoint Ops LLC5,055$0.77M0.0%N/A0.007%
2/16/2021Glenmede Trust Co. NA2,456$0.38M0.0%+61.6%0.003%
2/16/2021Armistice Capital LLC72,000$11.02M0.4%-64.7%0.095%
2/16/2021Morgan Stanley731,427$111.99M0.0%+45.3%1.027%
2/16/2021Tudor Investment Corp Et Al15,841$2.43M0.1%+126.9%0.022%
2/16/2021Nuveen Asset Management LLC33,706$5.16M0.0%-48.1%0.047%
2/16/2021Captrust Financial Advisors17,253$2.64M0.0%-1.3%0.024%
2/16/2021Vivaldi Capital Management LLC1,908$0.29M0.1%N/A0.003%
2/16/2021Guggenheim Capital LLC18,831$2.88M0.0%N/A0.026%
2/16/2021Price T Rowe Associates Inc. MD1,774,436$271.68M0.0%+8.8%2.492%
2/16/2021Clough Capital Partners L P145,007$22.20M1.6%-45.7%0.204%
2/16/2021Virginia Retirement Systems ET AL4,500$0.69M0.0%-70.2%0.006%
2/16/2021Hitchwood Capital Management LP75,000$11.48M0.2%N/A0.105%
2/16/2021ExodusPoint Capital Management LP5,842$0.89M0.0%N/A0.008%
2/16/2021Capital International Ltd.69,349$10.62M0.6%+1.3%0.097%
2/16/2021Fort Sheridan Advisors LLC1,457$0.22M0.1%N/A0.002%
2/13/2021Ancora Advisors LLC1,375$0.21M0.0%+292.9%0.002%
2/13/2021EMJ Capital Ltd.22,800$3.49M0.7%N/A0.032%
2/12/2021Stifel Financial Corp16,801$2.57M0.0%+33.0%0.024%
2/12/20211492 Capital Management LLC3,480$0.53M0.3%-62.5%0.005%
2/12/2021Brevan Howard Capital Management LP23,200$3.55M0.7%N/A0.033%
2/12/2021Bouvel Investment Partners LLC18,790$2.88M2.0%N/A0.026%
2/12/2021Brown Advisory Inc.3,022$0.46M0.0%N/A0.004%
2/12/2021Federated Hermes Inc.637,100$97.55M0.2%-17.1%0.895%
2/12/2021Raymond James Financial Services Advisors Inc.21,698$3.32M0.0%+42.1%0.030%
2/12/2021LPL Financial LLC56,532$8.66M0.0%+54.1%0.079%
2/12/2021Financial Advocates Investment Management1,377$0.21M0.0%N/A0.002%
2/12/2021Advisory Research Inc.7,444$1.14M0.1%-45.3%0.010%
2/12/2021Montag A & Associates Inc.4,302$0.66M0.0%+6.7%0.006%
2/12/2021Stevard LLC8,505$1.30M0.4%-27.6%0.012%
2/12/2021Change Path LLC6,508$1M0.1%N/A0.009%
2/12/2021Virtus ETF Advisers LLC1,966$0.30M0.1%-61.9%0.003%
2/12/2021M&T Bank Corp3,334$0.51M0.0%-60.4%0.005%
2/12/2021Mercer Global Advisors Inc. ADV2,565$0.39M0.0%N/A0.004%
2/11/2021Lazard Asset Management LLC850$0.13M0.0%N/A0.001%
2/11/2021Nikko Asset Management Americas Inc.3,836,823$587.46M3.3%+3.8%5.388%
2/11/2021B. Riley Wealth Management Inc.1,850$0.28M0.0%N/A0.003%
2/11/2021Northern Trust Corp47,913$7.34M0.0%+5.5%0.067%
2/11/2021Baird Financial Group Inc.1,992$0.31M0.0%N/A0.003%
2/11/2021Exencial Wealth Advisors LLC2,791$0.43M0.0%N/A0.004%
2/11/2021Lakeview Capital Partners LLC1,696$0.26M0.1%N/A0.002%
2/11/2021Handelsbanken Fonder AB8,900$1.36M0.0%-21.2%0.012%
2/11/2021Valeo Financial Advisors LLC3,737$0.57M0.0%-4.2%0.005%
2/11/2021Teacher Retirement System of Texas4,718$0.72M0.0%-84.2%0.007%
2/11/2021Slow Capital Inc.16,300$2.50M0.6%+1.7%0.023%
2/11/2021Steward Partners Investment Advisory LLC917$0.14M0.0%+145.8%0.001%
2/11/2021Oppenheimer & Co. Inc.9,088$1.39M0.0%-2.8%0.013%
2/11/2021Cresset Asset Management LLC12,180$1.87M0.0%+6.0%0.017%
2/11/2021Signaturefd LLC915$0.14M0.0%+14.4%0.001%
2/10/2021HighPoint Advisor Group LLC6,138$1.03M0.1%+4.2%0.009%
2/10/2021Renaissance Technologies LLC153,200$23.46M0.0%-61.2%0.215%
2/10/2021Mid Atlantic Financial Management Inc. ADV2,600$0.40M0.0%N/A0.004%
2/10/2021Harvey Capital Management Inc.2,500$0.38M0.2%N/A0.004%
2/10/2021Cookson Peirce & Co. Inc.17,183$2.63M0.2%+9.8%0.024%
2/10/2021KBC Group NV600$92K0.0%-50.0%0.001%
2/10/2021Advisor OS LLC2,010$0.31M0.1%N/A0.003%
2/10/2021Bluefin Capital Management LLC2,024$0.31M0.0%N/A0.003%
2/10/2021Bedell Frazier Investment Counseling LLC17,862$2.74M0.8%N/A0.025%
2/10/2021HighTower Advisors LLC26,471$4.05M0.0%+6.0%0.037%
2/10/2021Lisanti Capital Growth LLC5,560$0.85M0.1%N/A0.008%
2/10/2021Rikoon Group LLC4,913$0.30M0.1%+20.2%0.007%
2/9/2021Wells Fargo & Company MN464,518$71.12M0.0%-17.1%0.652%
2/9/2021Advisory Services Network LLC8,310$1.27M0.1%+628.3%0.012%
2/9/2021Nvwm LLC11,173$1.71M0.7%+2.2%0.016%
2/9/2021Bessemer Group Inc.1,538$0.24M0.0%N/A0.002%
2/9/2021D L Carlson Investment Group Inc.39,440$6.04M1.1%-18.0%0.055%
2/9/2021Bank of New York Mellon Corp39,847$6.10M0.0%-83.4%0.056%
2/9/2021Menard Financial Group LLC2,289$0.35M0.4%N/A0.003%
2/9/2021Merrion Investment Management Co LLC400$61K0.1%N/A0.001%
Data available starting January 2016

See Full Table
CRISPR Therapeutics logo
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, the company is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, it engages in the development of regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, myotonic dystrophy type 1, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc. The company was formerly known as Inception Genomics AG and changed its name to CRISPR Therapeutics AG in April 2014. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Read More

Today's Range

Now: $115.74
$114.32
$119.37

50 Day Range

MA: $125.44
$110.72
$148.98

52 Week Range

Now: $115.74
$42.83
$220.20

Volume

1,062,660 shs

Average Volume

2,238,456 shs

Market Capitalization

$8.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.37

Who are the company insiders with the largest holdings of CRISPR Therapeutics?

CRISPR Therapeutics' top insider shareholders include:
  1. Rodger Novak (President)
  2. Samarth Kulkarni (CEO)
  3. Lawrence Otto Klein (COO)
  4. Bradley J Phd Bolzon (Director)
  5. Tony W Ho (VP)
  6. Lawrence Otto Klein (Insider)
  7. Michael John Tomsicek (CFO)
  8. Pablo J Cagnoni (Director)
  9. James R Kasinger (General Counsel)
  10. Tony W Ho (VP)

Who are the major institutional investors of CRISPR Therapeutics?

CRISPR Therapeutics' top institutional shareholders include:
  1. Ipswich Investment Management Co. Inc. — 0.04%
  2. Liberty One Investment Management LLC — 0.00%
  3. Baldwin Brothers Inc. MA — 0.00%

Which institutional investors are selling CRISPR Therapeutics stock?

During the previous quarter, CRSP stock was sold by these institutional investors:
  1. Ipswich Investment Management Co. Inc.
In the last year, company insiders that have sold CRISPR Therapeutics company stock include:
  1. Rodger Novak (President)
  2. Samarth Kulkarni (CEO)
  3. Lawrence Otto Klein (COO)
  4. Bradley J Phd Bolzon (Director)
  5. Tony W Ho (VP)
  6. Lawrence Otto Klein (Insider)
  7. Michael John Tomsicek (CFO)
  8. Pablo J Cagnoni (Director)

Which institutional investors are buying CRISPR Therapeutics stock?

During the previous quarter, CRSP stock was acquired by institutional investors including:
  1. Liberty One Investment Management LLC
  2. Baldwin Brothers Inc. MA
Get out of cash NOW
Millionaire Wall Street Legend Urges Americans To Get Out Of CASH before April 27th.
Details here.
pixel